Pharmaceutical composition for treating chronic liver injury and application of pharmaceutical composition

A technology of chronic liver injury and composition, applied to the pharmaceutical composition for treating chronic liver injury and its application field

Inactive Publication Date: 2021-08-20
THE FIFTH MEDICAL CENT OF CHINESE PLA GENERAL HOSPITAL
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Liver fibrosis is an inevitable stage in the development of chronic liver disease to cirrhosis, and it is also a key link in the treatment of chronic liver disease. So far, there is no internationally recognized drug that is safe, effective, liver-targeted, and long-term tolerated by the FDA for use in human liver. fibrosis treatment

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for treating chronic liver injury and application of pharmaceutical composition
  • Pharmaceutical composition for treating chronic liver injury and application of pharmaceutical composition
  • Pharmaceutical composition for treating chronic liver injury and application of pharmaceutical composition

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0049] 1. Preparation of schisandra acetaminophen and curcumadione for cells: take appropriate amount of powder and dissolve them in DMSO respectively to make the final concentration of the mother solution 40mM, and place it at -20°C for later use. Dilute it with medium to dilute with different concentrations when used ( 0-40 μM).

[0050] 2. Preparation of Schisandra C and Curdione for animals: Weigh appropriate amount of Schisandra C and Curdione powder respectively, and make 200mg / kg and 50mg / kg of them with 5% sodium carboxymethyl cellulose solution. The solution for intragastric administration is prepared and used immediately.

[0051] 3. Preparation of APAP solution for cells: Take an appropriate amount of powder and dissolve it in the medium to make the concentration 20mM / L, and store it in the refrigerator at 4 degrees for later use.

[0052] 4. Preparation of each antibody protein: Dilute each antibody protein at a ratio of 1:1000, add sodium azide at a ratio of 1:10...

Embodiment 1

[0056] Inhibitory effect of schisandrin on APAP-induced oxidative stress in Hep G2 cells

[0057] Experimental procedure: Hep G2 cells after passage were divided into 1.5×10 5 cells / ml kind of 12-well plate, with a volume of 1ml per well, divided into blank wells and drug-treated wells, and after the second day’s wall-attachment was successful, the compound Schisandra C (0, 10, 20, 40uM) was added to the drug-treated wells respectively. ) 800ul for 6h (blank wells and control wells were added with an equal volume of drug diluent), and then 20Mm / L of APAP solution was added in the form of liquid exchange (blank wells were replaced with an equal volume of medium) for 12h. After gently aspirating the supernatant, add 150ul of trypsinized cells to each well, transfer to a new EP tube after digestion at 37°C for 1min, centrifuge at 1500rpm, discard the supernatant and wash with HBSS, then add the prepared MitoSOX TM The dye solution was incubated in a 37°C incubator for 15 minutes...

Embodiment 2

[0060] Specific regulatory effect of curcumadione on TGF-β / smad signaling pathway in LX-2 cells

[0061] Experimental procedure: the passaged LX-2 cells were divided into 2.5×10 5 cells / ml kind of 24-well plate with a volume of 500ul per hole, divided into blank wells and drug-treated wells, and the drug-treated wells were added with different concentrations of compound curcumadione (0, 10, 20, 40uM ) 500ul for 1h (add equal volume of drug diluent to blank wells and control wells), and then add 10ug / ml TGF-β stimulating factor to each well (add equal volume of medium to blank wells) for 24h. After gently aspirating the supernatant, add 150ul of 1×loading RIPA lysate to each well to lyse the cells. After scraping the cell lysate, put it in a metal bath at 105°C for 15min. The protein expression levels of TGF-β / smad signaling pathway-related proteins Collagen, α-SMA, and smad3 were detected by immunoblotting.

[0062] The subcultured LX-2 cells were seeded and treated in the s...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The application discloses a pharmaceutical composition for treating chronic liver injury and application of the pharmaceutical composition. Schisandrin C and curdione are used as active ingredients in the pharmaceutical composition, and the pharmaceutical composition optionally comprises pharmaceutically acceptable auxiliary materials. Meanwhile, the application further discloses application of the schisandrin C and curdione combined medicine in treating chronic liver injury such as hepatic fibrosis diseases.

Description

technical field [0001] This article involves but is not limited to medical technology, especially a pharmaceutical composition (with schisandrin and curcumadione as active ingredients) for the treatment of chronic liver injury and its application. Background technique [0002] Hepatic fibrosis (HF) is an active repair response of the body to chronic liver damage caused by chronic inflammation or other causes. If not intervened in time, it may lead to liver failure, liver cirrhosis and other liver failure diseases. When the liver is damaged, hepatic stellate cells (HSC) are activated in the hepatic sinusoidal space, and HSC activation is the key to the process of HF and is the main source of fibrous and non-fibrous matrix proteins. Activation of HSCs results in increased deposition of extracellular matrix (ECM), increased expression of contractile smooth muscle α-actin (α-SMA), release of pro-inflammatory cytokines, and expression of type I, III, and IV glial proteins , affe...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/36A61P1/16A61K31/122
CPCA61K31/36A61K31/122A61P1/16A61K2300/00
Inventor 柏兆方肖小河代炆璋徐广湛小燕李志勇丁凯欣
Owner THE FIFTH MEDICAL CENT OF CHINESE PLA GENERAL HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap